Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial).

Japanese journal of clinical oncology - 1 Jun 2024

Tsukita Yoko, Taguri Masataka, Goto Yasushi, Hosomi Yukio, Mizutani Tomonori, Watanabe Kageaki, Yoh Kiyotaka, Takahashi Satoshi, Kubota Kaoru, Kunitoh Hideo

Abstract excerpt

Osimertinib is the standard of care for patients with epidermal growth factor receptor-activating mutation-positive non-small cell lung cancer. Dose-toxicity has been previously reported, but no dose-response data within the range of 20-240 mg daily (mg/d). Thus, the current 80 mg/d dosing might be too high for elderly Japanese patients with an average body weight of only 50 kg, resulting in excessive toxicity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Dose-Response Relationship, Drug

Share to Indoles

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 38520037
DOI: 10.1093/jjco/hyae032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial).PMID 38520037Read ↗

Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.Semantic proximity Read ↗

Efficacy and safety of 40 mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study.Semantic proximity Read ↗

First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).Semantic proximity Read ↗

Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer.Semantic proximity Read ↗

Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.Semantic proximity Read ↗

Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting.Semantic proximity Read ↗

Reduced frequency dosing of osimertinib in EGFR-mutant non-small cell lung carcinoma: Real world dataSemantic proximity Read ↗

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.Semantic proximity Read ↗

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric StudySemantic proximity Read ↗

An updated cost-effectiveness analysis of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer: the perspective of the United States.Semantic proximity Read ↗

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.Semantic proximity Read ↗

Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.